Algebraic classification of seputinib/serpatinib among targeted drugs

Selpercatinib, trade nameRETEVMO, is a targeted drug used to treat cancers driven by RET gene mutations or fusions, and represents the first generation of RET inhibitors. Its main function is to selectively inhibit RET tyrosine kinase (RTK) to block the growth of cancer caused by RET gene mutations or rearrangements. Mutations or fusions of the RET gene play an important role in many types of cancer, especially in non-small cell lung cancer (NSCLC) and thyroid cancer. Therefore, targeted therapy against RET provides new treatment options for patients with these cancers.

As the first generation of RET inhibitors, seputinib and its similar drug pralsetinib (BLU-667) together represent the early stages of the development of this type of targeted drugs. These drugs target tumors with RET gene rearrangements or mutations, have strong specificity and selectivity, and can significantly improve the therapeutic effect, especially in patients with advanced cancer who are resistant to traditional chemotherapy drugs. Seputinib has shown high effectiveness in clinical trials, especially in the treatment of RET fusion-positive non-small cell lung cancer and medullary thyroid cancer. The response rate and survival time of patients have been prolonged.

Although the first generation RET inhibitors, such as seputinib, have achieved significant efficacy, they also have certain limitations. For example, some patients may develop drug resistance during treatment, especially after long-term treatment. This problem has prompted researchers to develop second- and third-generation RET inhibitors, which will further optimize their molecular structures to address some of the deficiencies in the first-generation drugs. Despite this, seputinib, as a first-generation drug, still occupies an important position in the treatment of RET-driven cancers.

Reference:https://en.wikipedia.org/wiki/Selpercatinib